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Objectives This study sought to explore the association between baseline levels of microRNAs (miRNAs) (1995) and inci-
dent myocardial infarction (1995 to 2005) in the Bruneck cohort and determine their cellular origin.
Background Circulating miRNAs are emerging as potential biomarkers. We previously identified an miRNA signature for type
2 diabetes in the general population.
Methods A total of 19 candidate miRNAs were quantified by real-time polymerase chain reactions in 820 participants.
Results In multivariable Cox regression analysis, 3 miRNAs were consistently and significantly related to incident myo-
cardial infarction: miR-126 showed a positive association (multivariable hazard ratio: 2.69 [95% confidence in-
terval: 1.45 to 5.01], p  0.002), whereas miR-223 and miR-197 were inversely associated with disease risk
(multivariable hazard ratio: 0.47 [95% confidence interval: 0.29 to 0.75], p  0.002, and 0.56 [95% confidence
interval: 0.32 to 0.96], p  0.036). To determine their cellular origin, healthy volunteers underwent limb
ischemia-reperfusion generated by thigh cuff inflation, and plasma miRNA changes were analyzed at baseline,
10 min, 1 h, 5 h, 2 days, and 7 days. Computational analysis using the temporal clustering by affinity propaga-
tion algorithm identified 6 distinct miRNA clusters. One cluster included all miRNAs associated with the risk of
future myocardial infarction. It was characterized by early (1 h) and sustained activation (7 days) post–
ischemia-reperfusion injury and consisted of miRNAs predominantly expressed in platelets.
Conclusions In subjects with subsequent myocardial infarction, differential co-expression patterns of circulating miRNAs
occur around endothelium-enriched miR-126, with platelets being a major contributor to this miRNA
signature. (J Am Coll Cardiol 2012;60:290–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.056MicroRNAs (miRNAs) are small noncoding RNAs that modify
gene expression at the post-transcriptional level. They bind to the
3=-untranslated regions of target messenger RNAs and induce
degradation or reduce translation efficiency of specific transcripts
(1,2). By now, miRNAs have emerged as key regulators of cardiac
growth, vascular development, and angiogenesis (3,4). Recent
studies also uncovered the presence of circulating miRNAs (5,6).
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July 24, 2012:290–9 MicroRNAs and Risk of Myocardial Infarctionevents. A total of 19 miRNAs were screened by quantitative
(real-time) polymerase chain reaction (qPCR) in the Bruneck
cohort, a large prospective, population-based study on cardio-
ascular disease. Baseline levels of 3 miRNAs (1995 evalu-
tion) were associated with the incidence of myocardial
nfarction (MI) over a 10-year observation period (1995 to
005). Additional miRNA measurements were performed
n healthy volunteers after thigh cuff-induced ischemia-
eperfusion injury (I/R). In this interventional study, the
miRNAs associated with the risk of future MI formed a distinct
cluster that predominantly originated from platelets.
Methods
Study subjects. The Bruneck study is a prospective,
population-based survey initiated in 1990 as a sex- and
age-stratified random sample of all inhabitants of Bruneck 40
to 79 years old (125 women and 125 men in their fifth to
eighth decades) (13). The current analysis focuses on the
1995 evaluation. Circulating miRNA levels were available in
820 of the 826 participants (99.3%). Follow-up in 2000 and
2005 was 100% complete for clinical endpoints and 90%
complete for repeated laboratory examinations. Fatal and
nonfatal MIs were ascertained following the World Health
Organization criteria for definite disease status (14) and did
not rely on hospital discharge codes or the patient’s self-
report but on a careful review of the medical records provided
by general practitioners, death certificates, and Bruneck Hos-
pital files. Diabetes was coded present if the individual had a
fasting glucose 140 mg/dl, a 2-h glucose level 200 mg/dl
after 75-g glucose load, or a pre-established, record-confirmed
diagnosis of diabetes. Systolic and diastolic blood pressure was
taken with a standard mercury sphygmomanometer after at
least 10 min of rest (the mean of 3 independent measure-
ments). Low-density lipoprotein cholesterol was assessed using
the Friedewald equation (15). For the interventional study,
healthy volunteers (n 11, 19 to 51 years old) underwent limb
I/R generated by thigh cuff inflation. Plasma samples were
taken at baseline, 10 min, 1 h, 5 h, 2 days, and 7 days after
injury. The protocols of both studies were approved by the
appropriate ethics committees, and all study subjects gave their
written informed consent before entering the study.
Taqman qPCR assay. MiRNAs were extracted using the
miRNeasy kit (Qiagen, Hilden, Germany) (12). A fixed
volume of 3 l of the 25 l RNA eluate was used as input
for reverse transcription reactions as described previously
(12). In brief, miRNAs were reversely transcribed using
Megaplex Primer Pools (Human Pools A version 2.1, Applied
Biosystems, Darmstadt, Germany). Reverse transcription
reaction products were further amplified using the Mega-
plex PreAmp Primers (Primers A v2.1). Both reverse
transcription and PreAmp products were stored at 20°C.
aqman miRNA assays were used to assess the expression
f individual miRNAs. Diluted pre-amplification product
0.5 l) was combined with 0.25 l Taqman miRNA assay
20) (Applied Biosystems) and 2.5 l Taqman Universal SPCR Master Mix No AmpErase
UNG (2) to a final volume of 5
l. qPCR was performed on an
Applied Biosystems 7900HT
thermocycler at 95°C for 10 min,
followed by 40 cycles of 95°C for
15 s and 60°C for 1 min. All
samples were run in duplicates.
Relative quantification was per-
formed using the software SDS2.2
(Applied Biosystems). U6 ex-
pression was used for normaliza-
tion purposes. In a second round,
the average cycle threshold (Ct)
value of all miRNAs was applied
as an additional normalization control. This commonly used
approach is expected to result in weaker associations because
levels of individual miRNAs and their clusters contribute to
the Ct average.
miRNA screening. Platelets, platelet-derived micropar-
ticles (PMPs), and peripheral blood mononuclear cells
were isolated from healthy subjects as previously described
(16). The pellet was lysed in Qiazol reagent, and the
extracted RNA was eluted in 25 l of nuclease free H2O.
Total RNA (20 ng) was used for reverse transcription. The
expression profile of platelets and PMPs was assessed using
the Human Taqman miRNA Array Card A (Applied
Biosystems) (12). Human umbilical vein endothelial cells
were purchased from Cambrex (Verviers, Belgium) and
cultured as previously described (16).
Cellular origin of plasma microparticles. Platelet-free
plasma was analyzed using a Guava 8HT flow cytometer
(Merck-Millipore, Billerica, Massachusetts), as described
previously (17). Microparticles (MPs) were characterized as
events with a diameter of 0.1 to 1.0 m identified using
egamix beads (0.5 to 3 m, Biocytex, Marseille, France)
and positively labeled by specific antibodies: anti-CD41-PC7
(0.05 g/test) from Beckman-Immunotech (Marseille, France);
anti-CD62E-FITC (0.2 g/test) from R&D Systems
Minneapolis, Minnesota); anti-CD144-PE (0.2 g/test)
from eBioscience (San Diego, California); or anti-CD235a-
APC (0.05 g/test) from BD Biosciences (Le Pont de
laix, France). Control experiments were performed using
heir respective isotypic fluorescent immunoglobulins.
Ps expressing phosphatidylserine were labeled using
nnexinV-APC (5 l/test; BD Pharmingen) in presence of
.5 mmol/l CaCl2. MP plasma concentration was assessed
sing Flowcount calibrator beads (Beckman Coulter,
illepinte, France). The following specific MP subpopula-
ions were defined: CD235a MPs (erythrocyte derived);
D144 or CD62E MPs (endothelial origin); and
D41 MPs (platelet derived).
tatistical analysis. Data were analyzed using the statisti-
al packages SPSS version 15.0 (SPSS Inc., Chicago,
llinois) and STATA version 10.1 (StataCorp, College
Abbreviations
and Acronyms
AIC  Akaike information
criterion
Ct  cycle threshold
I/R  ischemia-reperfusion
MI  myocardial infarction
miRNA  microRNA
MP  microparticle
PMP  platelet-derived
microparticle
qPCR  quantitative
polymerase chain reactiontation, Texas). Normally distributed continuous variables
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MicroRNAs and Risk of Myocardial Infarction July 24, 2012:290–9were presented as mean  SD, variables with a skewed
distribution as median (interquartile range) and dichoto-
mous variables as numbers and percentages. The Student t
est and Fisher exact test were used to analyze differences in
articipant characteristics between those in whom MI
eveloped during follow-up and those in whom it did not.
oge-transformed miRNAs were used for all computations
o approximate a Gaussian distribution. Correlations be-
ween miRNAs were assessed using Pearson correlation
oefficients with Bonferroni-adjusted p values. Cox propor-
ional hazard regression models were fitted to assess the
ssociation between loge-transformed miRNA levels and
ncident MI. To identify the subset or pattern of miRNA
ith the highest prognostic ability for future MI, 2 distinct
pproaches were used. 1) The first was a 2-step procedure.
o reduce the number of candidate miRNAs and subse-
uent computational requirements, forward and backward
tepwise Cox regression analyses with relaxed inclusion and
xclusion criteria (pentry 0.15 and premoval 0.20; adjusted
for age, sex, and previous cardiovascular disease) were fitted.
Seven miRNAs consistently detectable in the circulation
were selected in either or both of the analyses (miR-24,
miR-126, miR-140, miR-150, miR-197, miR-223, and
miR-486) and considered eligible for the second best subset
step. Cox regression models of all combinations of eligible
miRNAs were computed and compared according to the
models’ Akaike information criterion (AIC) that is based on
the maximized log-likelihood and imposes a penalty for
increasing the number of parameters in the model. Lower
values of AIC indicate the preferred model, which is the one
with the few parameters still providing adequate fit (trade-
off between accuracy and complexity). 2) The second
approach used the technique called L1 penalization, imple-
menting the least absolute shrinkage and selection operator
algorithm for all 19 miRNAs. L1-penalized methods shrink
the estimates of the regression coefficients toward 0 relative
to the maximum likelihood estimates. The technique has
been used to generate gene signatures from microarray data
to avoid overfitting arising from both collinearity and high
dimensionality. The amount of shrinkage is determined by
the tuning parameter 1, which is progressively increased to
he value that shrinks all regression coefficients to 0. Plots of
tted regression coefficients (y-axis) versus 1 (x-axis) were
enerated using the package ‘penalized’ of R statistical
oftware (18). The least absolute shrinkage and selection
ethod allows assessment of the relevance and robustness of
ndividual explanatory variables but produces biased esti-
ates for the regression coefficients. Accordingly, risk
stimates for the 3 miRNAs finally selected (both ap-
roaches identified the same miRNA signature) were com-
uted by standard Cox regression analysis and adjusted for
ge and sex, smoking status (ever vs. never smokers), systolic
lood pressure, low-density lipoprotein cholesterol, diabe-
es, and history of cardiovascular disease (multivariable
odel 1) plus other miRNAs (multivariable model 2) plusody mass index, waist-to-hip ratio, high-density lipopro-ein cholesterol, loge C-reactive protein, and fibrinogen
multivariable model 3). The incremental predictive value of
elected miRNAs over the Framingham Risk Score for hard
oronary heart disease as an endpoint was assessed by
alculating: 1) Harrell’s C-indices (19), a measure of dis-
rimination for censored time-to-event data; 2) the net
eclassification index (20); and 3) the integrated discrimi-
ation improvement (20). The net reclassification index was
alculated across the categories of predicted 10-year risk of
10%, 10% to 20%, and20%. In the interventional study,
iRNA expression profiles were clustered using the tem-
oral clustering by affinity propagation algorithm (21).
wo-sided p values 0.05 were considered significant.
esults
irculating miRNAs in the Bruneck Study. Baseline de-
ographic, clinical, and laboratory characteristics of the 820
articipants in the 1995 evaluation are shown in Online
able I. All subjects were of Caucasian origin. A total of 47
articipants experienced MI over the 10-year follow-up
eriod, corresponding to an incidence rate of 5.3 (95%
onfidence interval: 4.1 to 7.2) per 1,000 person-years. For
he initial screening, Human Taqman miRNA arrays
CardA version 2.1 and CardB version 2.0, Applied Bio-
ystems) covering 754 small noncoding RNAs were applied
o 8 pooled samples, consisting of subjects with and without
therosclerotic vascular disease matched for different cardio-
ascular risk factors (hypercholesterolemia, smoking, hyper-
ension, diabetes), as described previously (12). Of the 148
iRNAs with Ct values 36, 130 miRNAs were detected
sing fluidic CardA, and therefore all further analysis
ocused on this dataset. Our network analysis revealed 7
iRNAs as promising targets that were reliably detectable
n the circulation (12). These were selected and measured in
he entire Bruneck cohort (n  820). An additional 12
iRNAs were quantified as part of an ongoing project on
steoarthritis (n  820). miRNA levels were strongly
orrelated with each other, with some reaching almost
erfect correlation (e.g., miR-24 and miR-223, r  0.939).
he complex dependency of circulating miRNAs was fur-
her scrutinized as miRNA-miRNA correlation profiles
Online Fig. I).
ssociation with incident MI. miRNAs associated with
ncident MI were selected using 2 different approaches.
) Stepwise Cox regression with comparison of AIC, a
riterion considering both goodness of fit and the number of
arameters in the model, identified 2 preferred combina-
ions of miRNAs: miR-126/-197/-223 and miR-126/-
97/-24 (AIC 562 each with 6 degrees of freedom). 2) In
1-penalized Cox regression analysis, miR-126, miR-197,
and miR-223 showed the strongest associations with inci-
dent MI (Online Fig. II), whereas miR-24 performed
worse. Accordingly, we gave preference to the miR-126/-
197/-223 combination excluding miR-24. MiR-126 was
positively associated with incident MI, whereas miR-197
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July 24, 2012:290–9 MicroRNAs and Risk of Myocardial Infarctionand miR-223 were inversely related to disease risk (Fig. 1).
Similar results were obtained after normalization to the
average Ct value of all assessed miRNAs (Online Fig. III).
There was no effect modification by sex or pre-existing
cardiovascular disease (Online Table II). When the other
miRNAs were individually added to the multivariable
model already including miR-126/-197/-223, none
achieved statistical significance (Online Fig. IV). In suba-
nalysis, miR-223 showed a stronger association with fatal
than nonfatal MI (Fig. 2A) but was equally associated with
early (1995 to 2000) and late (2000 to 2005) events (Fig.
2B). In contrast, miR-126 and miR-197 were predomi-
nantly associated with early events (Fig. 2B). These findings
were similar for normalization to U6 or the average Ct value
of all miRNAs (Online Fig. V) and replicated when the
time period was divided into smaller intervals (1995 to
1997, 1997 to 2000, 2000 to 2005; Online Fig. VI).
Findings for cardiovascular death and less so for all-cause
death were similar to those for MI (Online Fig. VII).
Findings for stroke, however, were different, possibly due to
its heterogeneous origin (cardiac embolism and microangi-
opathy vs. atherothrombosis).
MI risk reclassification. Addition of the 3 miRNAs to a
base model of the Framingham Risk Score for hard coro-
nary heart disease as an endpoint increased the C-index
from 0.763 (95% confidence interval [CI]: 0.702 to 0.824)
to 0.800 (95% CI: 0.743 to 0.856) (	0.037, p  0.171). In
comparison, the gain for loge-transformed high-sensitivity
-reactive protein levels was only 	0.005. The net reclas-
ification improvement was 16.86% (1.99% to 35.71%)
Figure 1 Risk Estimates for the 3 miRNAs Most Consistently A
The 3 miRNAs were identified by Akaike Information Criterion–based models and t
derived from standard Cox regression models with progressive adjustment (for det
tion to cycle threshold average, see Online Figure III). CI  confidence interval; HRp  0.080). The integrated discrimination improvement mas 0.047 (95% CI: 0.005 to 0.089) (p 0.029). Details are
iven in Tables 1 and 2. In subjects with incident MI (n 
7), 14 were correctly reclassified to a higher risk category
nd 6 were reclassified to a lower category (p  0.074). In
articipants who had no MI (n  628), 38 were correctly
eclassified to a lower risk category and 39 were reclassified
o a higher category (p  0.909) (10-year risk categories
10%, 10% to 20%, and 20%).
nterventional study. To explore the cellular origin of
irculating miRNAs, healthy volunteers (n  11) under-
ent limb I/R generated by cuff inflation. Their clinical
haracteristics are shown in Online Table III. Samples were
ollected at baseline and 10 min, 1 h, 5 h, 2 days, and 7 days
fter injury (Fig. 3A). Thirty miRNAs, including the
iRNAs associated with MI in the Bruneck study, were
ssessed by qPCR. Computational analysis using the tem-
oral clustering by an affinity propagation algorithm based
n average miRNA expression at baseline and over time
dentified 6 distinct miRNA clusters (Fig. 3B). Cluster 2
as of particular interest: all miRNAs associated with future
Is (miR-126, miR-223, miR-197, and miR-24) were part
f this cluster characterized by an early increase at 1 h and
ustained elevation until 7 days post I/R injury (Fig. 4).
iR-21 was also included. Results were robust with differ-
nt methods of normalization (exogenous spike-in cel-
iR-39 control and unadjusted Ct values). The response
f the other miRNAs to I/R injury is shown in Online
ig. VIII.
latelet contribution. I/R injury induces platelet activa-
ion (22,23), and platelets were recently shown to contain
iated With MI
hnique of least absolute shrinkage and selection operator. HR (95% CI) were
ee Methods). Expression levels were normalized to U6 expression (for normaliza-
zard ratio; MI  myocardial infarction.ssoc
he tec
ails, s
 haiRNAs (24,25). To test for a potential platelet contribu-
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MicroRNAs and Risk of Myocardial Infarction July 24, 2012:290–9tion to the observed miRNA changes after I/R, miRNA
screening was performed in preparations of platelets and
PMPs derived from thrombin-activated platelets. The miRNAs
constituting our cluster of interest (miR-223, -126, -24,
-21, and -197) were among the miRNAs highly expressed
in platelets (Fig. 5A) and PMPs (Fig. 5B). A comparison
with peripheral blood mononuclear cells and endothelial
cells confirmed that miR-223 was predominantly found in
platelets, whereas miR-197 and miR-24 were also present in
endothelial cells. In contrast, miR-126 and miR-21 were
highly enriched in endothelial cells, but detectable in platelets,
albeit at much lower concentrations (Fig. 5C, upper panel).
The platelet origin of these circulating miRNAs was further
supported by a significant correlation (except miR-21) with
PMP counts 2 days after I/R injury (Fig. 5C, lower panel).
Hence, adjustment for platelet-derived miRNAs may refine
the endothelial contribution to the miR-126 content in the
circulation. This is in agreement with our results from the
Figure 2 Subanalysis for Cases of MI
Subanalysis for fatal versus nonfatal MI (A) and early (1995 to 2000) versus
late (2000 to 2005) events (B). HR (95% CI) were derived from multivariable
Cox regression model 2, including miR-126, miR-197, and miR-223 (for details,
see Methods). During 10 years of follow-up (1995 to 2005), there were 26
fatal and 21 nonfatal MIs. There were 17 MIs during follow-up period 1995 to
2000 (incidence rate, 3.7 [range, 2.2 to 5.9] per 1,000 person-years) and 30
MIs during the period 2000 to 2005 (incidence rate, 7.4 [range, 5.2 to 10.6]
per 1,000 person-years). Expression levels were normalized to U6 expression
(for normalization to Ct average, see Online Figure V). Abbreviations as in Figure 1.Bruneck study, in which adjustment for miR-197 and miR-223 exposed the opposing directionality of changes in miR-126
in participants with subsequent MI (Fig. 1).
Discussion
This is the first prospective study on the association of
circulating miRNAs and incident MI with miR-223 and
miR-197 showing negative associations and miR-126
showing a positive association with subsequent MIs.
Prediction of cardiovascular events. There are currently
few biomarkers that could be used to identify subjects who are
at risk of the development of acute manifestations of cardio-
vascular disease. Despite extensive studies and development of
several risk prediction models, traditional risk factors fail to
predict cardiovascular events in a large group of cases. Inflam-
Reclassification of Study Participants Into MI RiskGroup by Additi n of miR-126, miR-197, and m R-223to a Model With the FRS for Hard Coro ary HeartDise e
Table 1
Reclassification of Study Participants Into MI Risk
Groups by Addition of miR-126, miR-197, and miR-223
to a Model With the FRS for Hard Coronary Heart
Disease
Model With FRS Score Plus miR-126, miR-197,
and miR-223
<10% Risk 10%–20% Risk >20% Risk Total
Model With FRS No. (Row Percentage)
Participants who
experienced an
MI event, % risk
10 20 (69.0) 8 (27.6) 1 (3.4) 29
10–20 3 (27.3) 3 (27.3) 5 (45.4) 11
20 1 (14.3) 2 (28.6) 4 (57.1) 7
Total 24 13 10 47
Participants who did not
experience an
MI event, % risk
10 522 (94.4) 28 (5.1) 3 (0.5) 553
10–20 31 (52.5) 20 (33.9) 8 (13.6) 59
20 2 (12.5) 5 (31.2) 9 (56.3) 16
Total 555 53 20 628
Framingham Risk Score for the hard coronary heart disease endpoint; 145 participants were not
included in the analysis because they were censored before 10 years of follow-up not due to a
myocardial infarction.
FRS  Framingham Risk Score; MI  myocardial infarction.
Summary Statistics of MI Risk Reclassificationby Addition of miR-126, mi -197, and miR-223to a Model With the FRS for Hard CoronaryHe rt Dis ase
Table 2
Su mary Statistics of MI Risk Reclassification
by Addition of miR-126, miR-197, and miR-223
to a Model With the FRS for Hard Coronary
Heart Disease
Statistic Estimate 95% CI p Value
Net reclassification
improvement
Controls 0.16% 2.90% to 2.58% 0.909
Cases 17.02% 1.63% to 35.67% 0.074
Overall 16.86% 1.99% to 35.71% 0.080
Integrated discrimination
improvement
Controls 0.003331 0.000364–0.006297 0.028
Cases 0.043967 0.001742–0.086191 0.041
Overall 0.047297 0.004969–0.089626 0.029CI  confidence interval; other abbreviations as in Table 1.
295JACC Vol. 60, No. 4, 2012 Zampetaki et al.
July 24, 2012:290–9 MicroRNAs and Risk of Myocardial Infarctionmatory markers such as high-sensitivity C-reactive protein lack
specificity for the vasculature. Advanced imaging techniques
are expensive and not suitable for population-wide screening.
In addition, atherosclerosis is a diffuse disorder with various
local and systemic manifestations. Thus, there is a clinical need
for cardiovascular biomarkers that could complement the
assessment of traditional risk factors.
miRNAs as biomarkers for MI. In our analysis, we
considered 7 miRNAs that emerged as promising targets for
cardiovascular disease in the pre-screening and displayed
unique network topology (12). Three of these miRNAs
formed part of a signature for MI: miR-126, miR-197, and
Figure 3 Interventional Study to Identify miRNA Clusters
(A) Model of limb ischemia-reperfusion injury in healthy volunteers. Arrows indicat
(B) miRNA clusters. Temporal clustering by affinity propagation grouped the 30 mimiR-223. Our findings were independent of classic vascularrisk factors, stable in subgroups (men and women, partici-
pants with and without previous cardiovascular disease) and
robust when using distinct statistical approaches. Another
12 miRNAs were not related to atherosclerotic vascular
disease in the pre-screening and fell short of significance in
the main analysis. miR-223 is considered to be a myeloid-
specific miRNA that acts as a fine tuner of granulocyte
production and the inflammatory response (26–28). miR-
197 has been reported as differentially expressed in tumors
(29,30). In contrast, miR-126 is highly enriched in endo-
thelial cells and facilitates vascular endothelial growth factor
signaling (31). However, little is known about the cellular
points of sample collection.
into 6 distinct clusters. miRNA  microRNA.e time
RNAsorigin of these miRNAs in the circulation.
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MicroRNAs and Risk of Myocardial Infarction July 24, 2012:290–9miRNA response after I/R injury. Based on expression
profiles after I/R injury, miR-126, miR-197, and miR-223
were part of 1 cluster that also included miR-21 and
miR-24. All these miRNAs are highly expressed in platelets
and PMPs. This is, to our knowledge, the first time that the
contribution of a specific cell type to circulating miRNAs
has been defined by a controlled intervention. The present
Figure 4 miRNA Cluster Associated With MI
Cluster 2 contained all miRNAs associated with MI. Temporal changes were asses
was used as a normalization control. Red bars indicate statistically significant difffindings extend our previous observations in patients withdiabetes (12) and raise the possibility that the observed loss
of several miRNAs, including miR-126, miR-197, miR-
223, miR-24, and miR-21, may reflect abnormal platelet
function in diabetic patients. A reduction of platelet miR-
NAs could reflect a decrease in the miRNA content of
platelets, increased clearance of PMPs by inflammatory
cells, or impaired thrombus resolution. In contrast, changes
y quantitative polymerase chain reaction. Exogenous spike-in cel-miR-39
s (p  0.05) compared with baseline. Abbreviations as in Figures 2 and 3.sed b
erencein miR-126 in participants with future MI did not follow
297JACC Vol. 60, No. 4, 2012 Zampetaki et al.
July 24, 2012:290–9 MicroRNAs and Risk of Myocardial Infarctionthe same directionality as miR-197 and miR-223, arguing
against a common platelet origin. Higher levels of circulat-
ing miR-126 could be in line with previous reports impli-
cating endothelial MPs as biomarkers for vascular damage
and increased cardiovascular risk (32). Regardless, our
findings advise caution in interpreting individual miRNA
changes in isolation. Because circulating miRNAs are highly
Figure 5 Platelet Contribution to miRNA Signature for MI
(A) miRNA profile of platelets, as determined by microarray screening. The averag
formed. (B) Corresponding miRNA profile of PMPs. miRNAs associated with myoca
expression. Comparison of miR-126, miR-223, miR-197, miR-21, and miR-24 expr
cells (ECs) using quantitative polymerase chain reaction (upper panel). Ct values
miRNA levels with PMP counts (lower panel) at baseline (blue dots) and 2 days p
0.05. Ct  cycle threshold; miRNA  microRNA; PMPs  platelet-derived micropacorrelated, global patterns of expression should be studiedby representing miRNA data as coexpression networks.
miRNA signatures rather than individual miRNAs may be
more reliable biomarkers for cardiovascular events.
The underexplored role of miRNAs in platelets. It is
noteworthy that several of the most abundant platelet
miRNAs have previously been implicated in cardiovascular
pathologies: miR-126 as a master regulator of endothelial
lue was used as a normalization control. Expression levels (2-DCt) were log trans-
nfarction (MI) were abundant in platelets and PMPs. (C) Cell type–specific miRNA
in peripheral blood mononuclear cells (PBMCs), platelets (PLTs), and endothelial
vided as mean  SD derived from 3 independent preparations. Correlation of
injury (red dots). R values are Pearson correlation coefficients (n  11). *p e Ct va
rdial i
ession
are pro
ost I/R
rticles.homeostasis and vascular integrity (33), miR-21 as a medi-
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others (35), and miR-24 as an inducer of endothelial
apoptosis after myocardial infarction (36). Although the
functional importance of platelet miRNAs is currently
unknown, it is conceivable that systemic inhibition of
miRNAs, which are also abundant in platelets, may alter
platelet function and contribute to the observed cardiovas-
cular phenotypes. The presence of these miRNAs within
platelets should be taken into account in future studies.
Also, care must be taken in the design of case-control
studies for biomarker analysis. Comparisons of circulating
miRNAs between patients with manifest cardiovascular
disease and healthy controls, for example, are likely to be
confounded by medication, in particular, antiplatelet
therapy.
Study limitations. Our findings await confirmation in
ndependent cohorts. Thus, their exploratory/hypothesis-
enerating nature has to be emphasized. Two conservative
pproaches were used for reliable miRNA selection. Both
ethods returned the same 3 miRNAs. A model including
hese 3 miRNAs plus age and sex captured the entire
nformation (5 variables for 47 endpoints). Additional
djustment for other cardiovascular risk factors had almost
o effect on risk estimates and little effect on the respective
tandard errors. Nonetheless, a risk of overfitting of data
emains and risk relationships emerged only after adjust-
ent, which highlights one of the challenges in miRNA
esearch (37). Also, causality cannot be inferred from
ssociations of biomarkers in population studies.
onclusions
his study highlights the importance of platelets as a major
ontributor to the circulating miRNA pool and suggests
hat endothelial-enriched miR-126 is part of a miRNA
ignature associated with incidence of MI in the general
opulation. Future studies will need to address whether
ndothelial and platelet miRNAs can serve as novel bio-
arkers for clinical decision making.
Reprint requests and correspondence: Dr. Manuel Mayr, King’s
British Heart Foundation Centre, King’s College London, 125
Coldharbour Lane, London SE59NU, United Kingdom. E-mail:
manuel.mayr@kcl.ac.uk.
REFERENCES
1. Bartel DP. MicroRNAs: target recognition and regulatory functions.
Cell 2009;136:215–33.
2. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein
synthesis by miRNAs: how many mechanisms? Trends Cell Biol
2007;17:118–26.
3. Zampetaki A, Mayr M, MicroRNAs in vascular and metabolic disease.
Circ Res 2012;110:508–22.
4. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs
in cardiovascular biology. Circ Res 2007;101:1225–36.
5. Mitchell PS. Circulating microRNAs as stable blood-based markers
for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513–8.6. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs,
potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci
U S A 2009;106:4402–7.
7. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential
novel biomarker for acute myocardial infarction. Biochem Biophys Res
Commun 2010;391:73–7.
8. D’Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs
are new and sensitive biomarkers of myocardial infarction. Eur Heart J
2010;31:2765–73.
9. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in
patients with coronary artery disease. Circ Res 2010;107:677–84.
10. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a
circulating biomarker for heart failure. Circ Res 2010;106:1035–9.
11. Wang GK. Circulating microRNA: a novel potential biomarker for
early diagnosis of acute myocardial infarction in humans. Eur Heart J
2010;31:659–66.
12. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma MicroRNA profiling
reveals loss of endothelial MiR-126 and other MicroRNAs in type 2
diabetes. Circ Res 2010;107:810–7.
13. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymor-
phisms and atherogenesis. N Engl J Med 2002;347:185–92.
14. World Health Organization, Working Group on the Establishment of
Ischemic Heart Disease Registers. Report of the Fifth Working
Group, Copenhagen. In: Report no. Eur 8201 (5). World Health
Organization, Geneva, 1971.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concen-
tration of low-density lipoprotein cholesterol in plasma, without use of
the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
16. Prokopi M, Pula G, Mayr U, et al. Proteomic analysis reveals presence
of platelet microparticles in endothelial progenitor cell cultures. Blood
2009;114:723–32.
17. Amabile N, Guerin AP, Leroyer A, et al. Circulating endothelial
microparticles are associated with vascular dysfunction in patients with
end-stage renal failure. J Am Soc Nephrol 2005;16:3381–8.
18. Goeman JJ. L1 penalized estimation in the Cox proportional hazards
model. Biom J 2010;52:70–84.
19. Fibrinogen Studies Collaboration. Measures to assess the prognostic
ability of the stratified Cox proportional hazards model. Stat Med
2009;28:389–411.
20. Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS.
Evaluating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond. Stat Med
2008;27:157–72; discussion 207–12.
21. Kiddle SJ, Windram OP, McHattie S, et al. Temporal clustering by
affinity propagation reveals transcriptional modules in Arabidopsis
thaliana. Bioinformatics 2010;26:355–62.
22. Collins P, Ford I, Greaves M, Macaulay E, Brittenden J. Surgical
revascularisation in patients with severe limb ischemia induces a
pro-thrombotic state. Platelets 2006;17:311–7.
23. Massberg S, Enders G, Matos FC, et al. Fibrinogen deposition at the
postischemic vessel wall promotes platelet adhesion during ischemia-
reperfusion in vivo. Blood 1999;94:3829–38.
24. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P.
Existence of a microRNA pathway in anucleate platelets. Nat Struct
Mol Biol 2009;16:961–6.
25. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA
coexpression profiles correlate with platelet reactivity. Blood 2011;117:
5189–97.
26. Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor
cell proliferation and granulocyte function by microRNA-223. Nature
2008;451:1125–9.
27. Pulikkan JA. Cell-cycle regulator E2F1 and microRNA-223 comprise
an autoregulatory negative feedback loop in acute myeloid leukemia.
Blood 2010;115:1768–78.
28. Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH. miR-223 and
miR-142 attenuate hematopoietic cell proliferation, and miR-223
positively regulates miR-142 through LMO2 isoforms and CEBP-
beta. Cell Res 2010;20:1158–69.
29. Lehmann U, Streichert T, Otto B, et al. Identification of differentially
expressed microRNAs in human male breast cancer. BMC Cancer
2010;10:109.
30. Scapoli L, Palmieri A, Lo Muzio L, et al. MicroRNA expression
profiling of oral carcinoma identifies new markers of tumor progres-
sion. Int J Immunopathol Pharmacol 2010;23:1229–34.
299JACC Vol. 60, No. 4, 2012 Zampetaki et al.
July 24, 2012:290–9 MicroRNAs and Risk of Myocardial Infarction31. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angio-
genic signaling and vascular integrity. Dev Cell 2008;15:272–84.
32. Rautou PE, Vion AC, Amabile N, et al. Microparticles, vascular
function, and atherothrombosis. Circ Res 2011;109:593–606.
33. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific
microRNA miR-126 governs vascular integrity and angiogenesis. Dev
Cell 2008;15:261–71.
34. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to
myocardial disease by stimulating MAP kinase signalling in fibro-
blasts. Nature 2008;456:980–4.
35. Patrick DM, Montgomery RL, Qi X, et al. Stress-dependent cardiac
remodeling occurs in the absence of microRNA-21 in mice. J Clin
Invest 2010;120:3912–6.36. Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates
vascularity after myocardial infarction. Circulation 2011;124:720–30.
37. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of
circulating microRNAs: from single biomarkers to re-wired networks.
Cardiovasc Res 2012;93:555–62.
Key Words: biomarker y endothelium y microRNA y myocardial
infarction y platelets.
APPENDIXFor supplemental tables, please see the online version of this article.
